Intraocular pressure reduction with topical medications and progression of normal-tension glaucoma: a 12-year mean follow-up study

2013 ◽  
Vol 91 (4) ◽  
pp. e270-e275 ◽  
Author(s):  
Martha Kim ◽  
Dong Myung Kim ◽  
Ki Ho Park ◽  
Tae-Woo Kim ◽  
Jin Wook Jeoung ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Normal Tension Glaucoma ◽  
Pressure Reduction ◽  
Follow Up Study ◽  
Intraocular Pressure Reduction ◽  
Topical Medications

Intraocular Pressure Reduction in the Treatment of Normal-Tension Glaucoma

2020 ◽  
pp. 67-72
Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins
Keyword(s):  
Clinical Trial ◽  
Intraocular Pressure ◽  
Visual Field ◽  
Natural History ◽  
Visual Loss ◽  
Normal Tension Glaucoma ◽  
Pressure Reduction ◽  
Glaucomatous Damage ◽  
Intraocular Pressure Reduction ◽  
History Of

The Collaborative Normal-Tension Glaucoma Study (CNTGS) was a randomized clinical trial to determine the effectiveness of a 30% reduction in intraocular pressure (IOP) (using either medical therapy or filtration surgery) on visual field (VF) progression in eyes with normal-tension glaucoma. The study found that reducing the IOP of patients with normal-tension glaucoma by 30% is beneficial to prevent progression of glaucomatous damage if the visual effects of cataracts are excluded from consideration. However, because not all untreated patients progressed, the natural history of normal-tension glaucoma must be considered before embarking on IOP reduction with therapy that may exacerbate cataract formation, unless normal-tension glaucoma threatens serious visual loss.

Intraocular pressure reduction in normal-tension glaucoma patients in South Korea

2011 ◽  
Vol 31 (5) ◽  
pp. 355-361 ◽  
Author(s):  
Kyoung Tak Ma ◽  
Chan Yun Kim ◽  
Gong Je Seong ◽  
Seung Hyuck Lee ◽  
Jong Woon Park ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
South Korea ◽  
Normal Tension Glaucoma ◽  
Pressure Reduction ◽  
Intraocular Pressure Reduction

Potential Benefit of Intraocular Pressure Reduction in Normal-Tension Glaucoma in South Korea

2009 ◽  
Vol 25 (1) ◽  
pp. 91-96 ◽  
Author(s):  
Gong Je Seong ◽  
Sae Heun Rho ◽  
Chang Sik Kim ◽  
Jong Il Moon ◽  
Michael Scott Kook ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
South Korea ◽  
Potential Benefit ◽  
Normal Tension Glaucoma ◽  
Pressure Reduction ◽  
Intraocular Pressure Reduction

scholarly journals Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma

2016 ◽  
Vol 33 (3) ◽  
pp. 435-446 ◽  
Author(s):  
Tomoko Naito ◽  
Shinichi Okuma ◽  
Mikio Nagayama ◽  
Shiro Mizoue ◽  
Mineo Ozaki ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Ophthalmic Solution ◽  
Normal Tension Glaucoma ◽  
Pressure Reduction ◽  
Intraocular Pressure Reduction

Comparison of performance between two microcatheter systems in ab externo canaloplasty: A retrospective comparison study

2019 ◽  
Vol 30 (3) ◽  
pp. 487-493
Author(s):  
Iraklis Vastardis ◽  
Kalliopi Kontopoulou ◽  
Sofia Fili ◽  
Zisis Gatzioufas ◽  
Markus Kohlhaas
Keyword(s):  
Intraocular Pressure ◽  
Drug Therapy ◽  
Group Formation ◽  
Pairwise Comparison ◽  
Pressure Reduction ◽  
Intraocular Pressure Reduction ◽  
Kaplan Meier ◽  
Phakic Eyes ◽  
Selection Of

Purpose: To compare the performance of two different microcatheter systems, iTrack™ 250A and Glaucolight, in ab externo canaloplasty in three major categories: intraocular pressure reduction, drug therapy reintroduction, and evaluation of viscodilation over distension of the inner wall of Schlemm’s canal. Methods: A total of 56 and 46 eyes from different glaucoma types underwent ab externo canaloplasty using two different microcatheter systems. Group formation was made according to microcatheter system used. Kaplan–Meier test was performed for drug therapy reintroduction in relation to the two microcatheters. Tests of between-subject effects in two-way analysis of variance evaluated the efficacy of the two microcatheters and their features in relation to intraocular pressure reduction. Results: Kaplan–Meier test was not statistically significant (p = 0.20) regardless of microcatheter system. Tests of between-subject effects in relation to intraocular pressure reduction was not statistically different between the two microcatheters (p = 0.26) or between microcatheter and follow-up (p = 0.90). Intraocular pressure reduction in different glaucoma type was statistically significant during the follow-up period and glaucoma types showed different results between them in relation to follow-up (p < 0.001 and p = 0.002, respectively), but the pairwise comparison was not statistically important (p = 0.42). Intraocular pressure reduction was better in pseudophakic eyes in comparison with phakic eyes (p = 0.03), but the selection of microcatheter seemed not to affect this result (p = 0.11 and p = 0.32, respectively). Conclusion: Both microcatheter systems performed equal in terms of intraocular pressure reduction. Drug therapy reintroduction was not affected by the selection of the two microcatheters. Different types of glaucoma responded different to canaloplasty. Pseudophakic eyes responded better to treatment than phakic eyes, but the microcatheter selection seemed not affect this result.

scholarly journals The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study

2020 ◽  
Author(s):  
Yue Guo ◽  
Jun Young Ha ◽  
Helong Piao ◽  
Mi Sun Sung ◽  
Sang Woo Park
Keyword(s):  
High Risk ◽  
Normal Tension Glaucoma ◽  
Meibomian Gland ◽  
Upper Eyelid ◽  
Follow Up Study ◽  
Promising Strategy ◽  
Imagej Software ◽  
Topical Medications ◽  
Preservative Free

Abstract Background To determine if 3% diquafosol (DQS) can preserve the meibomian gland morphology in glaucoma patients treated with prostaglandin analogs (PGA) for a 12-month follow-up period. Methods This study included 84 eyes of 46 normal tension glaucoma (NTG) patients who were treated with either preservative-containing PGA (PC-PGA; 16 patients, 28 eyes), preservative-free PGA (PF-PGA; 21 patients, 39 eyes), or a combination of PC-PGA and 3% DQS (PC-PGA + DQS; 9 patients, 17 eyes). The meibography of the upper eyelid was acquired using Keratograph® 5M at baseline and at each follow-up (1, 3, 6, 9, and 12 months). Meibomian gland loss (MGL) was quantitatively analyzed by using ImageJ software. Results In the PC-PGA group, MGL increased significantly from baseline to month 9 and month 12, whereas no significant changes were observed in the PF-PGA and PC-PGA + DQS groups during the entire 12 months. All groups showed similar MGL at each follow-up time from baseline to six months. However, MGL in the PC-PGA group was significantly higher than those in the PF-PGA and PC-PGA + DQS groups at the 9 and 12 months. Conclusions Combining 3% DQS with PC-PGA was as effective as PF-PGA in preserving the meibomian gland morphology for at least 12 months. Our results suggest that 3% DQS may be a promising strategy for managing glaucoma patients with a high risk of developing meibomian gland dysfunction due to preservative-containing topical medications.

One-year follow-up of the XEN® implant with mitomycin-C in pseudoexfoliative glaucoma patients

2018 ◽  
Vol 29 (3) ◽  
pp. 309-314 ◽  
Author(s):  
Ana Ibáñez-Muñoz ◽  
Víctor Santiago Soto-Biforcos ◽  
María Chacón-González ◽  
Oscar Rúa-Galisteo ◽  
Alexandra Arrieta-Los Santos ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Mitomycin C ◽  
Primary Outcome ◽  
Primary Outcome Measure ◽  
Pressure Reduction ◽  
Pseudoexfoliative Glaucoma ◽  
Intraocular Pressure Reduction ◽  
Pressure Lowering ◽  
One Year

Purpose: To evaluate the intraocular pressure–lowering effect, the safety profile, and the success rate of the XEN45 Gel Stent (Allergan, Dublin, Ireland) in patients with pseudoexfoliative glaucoma. Methods: Retrospective study conducted on patients with pseudoexfoliative glaucoma, with or without cataract, who underwent XEN45 implantation surgery with subconjunctival mitomycin-C and had a minimum postoperative follow-up period of 12 months. The primary outcome measure was intraocular pressure reduction at 1 year as compared to baseline. Complete success was defined as a postoperative intraocular pressure reduction of ⩾20% from preoperative baseline at 12 months without any glaucoma medications. Qualified success was defined as a postoperative intraocular pressure reduction of ⩾20% at 12 months with medications. Results: Of the 24 screened patients, 21 eyes of 20 patients met the inclusion/exclusion criteria and were included in the study. A total of 13 (62%) eyes underwent XEN alone surgery and 8 (38%) eyes had combined XEN + cataract surgery. Mean intraocular pressure was significantly reduced from 21.1 (3.8) mmHg at baseline to 15.2 (3.9) mmHg at 1 year, p < 0.001. Mean antiglaucoma medications dropped from 2.95 (0.97) preoperatively to 1.23 (1.22) at month 12 (p < 0.001). Of the 21 eyes included in the study, 18 (85.7%) were considered as success, 6 (28.6%) as complete success, and 12 (57.1%) as qualified success. Five eyes required needling revision. Complications included uveitis, choroidal detachment, hyphema, and cystoid macular edema in 2, 1, 1, and 1 eye, respectively. Conclusion: XEN45 Gel Stent implant significantly reduced the intraocular pressure and the number of antiglaucoma medications in patients with pseudoexfoliative glaucoma.

Sign in / Sign up

Export Citation Format

Share Document